Pharm-Olam International Ltd., a global, full service CRO to the pharmaceutical and biotech industries is pleased to announce plans to aggressively explore the acquisition of other CROs and industry technology providers.

Pharm-Olam International is excited to announce their new Strategic Development Director, Matt Delaney.  Mr. Delaney has over 20 years of experience in strategic planning and development of new market segments in healthcare, life sciences and the computer industry. “Matt’s experience bringing several companies under one umbrella will prove invaluable as we broaden our core CRO offerings and strengthen our presence through acquisitions,” said Dr. Zev Munk, CEO.

Mr. Delaney previously served as Director of Corporate Strategy for Dell Computer for ten years, reporting directly to Dell’s CEO.  During this assignment Dell experienced extraordinary growth from $7 billion to more than $28 billion over a four year period.  Mr. Delaney has an MBA and a Masters Certification in International Business.

For further information about conducting trials with Pharm-Olam please contact Matt Delaney at matt.delaney@pharm-olam.com or John Hovre, Chief Operating Officer, at john.hovre@pharm-olam.com

About Pharm-Olam International

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.